A b s t r a c t Pulmonary fibrosis, represented mainly by idiopathic pulmonary fibrosis, develops chronic and progressive changes in lung parenchyma with high mortality and limited therapeutic options. The aim of this review was to summarize the most common experimental models used in the research of pulmonary fibrosis. Lung damage associated with development of pulmonary fibrosis can be caused by irradiation or by instillation of bleomycin, fluorescein isothiocyanate (FITC), silicon dioxide (silica), asbestos, etc. This article reviews the characteristics of the most frequently used animal models of fibrosis, including the limitations of their use. Although none of the used animal models resembles completely the changes in human pulmonary fibrosis, similarities between them allow preclinical testing of novel treatment approaches or their combinations in the laboratory conditions before their use in the clinical practice.
INTRODUCTION

Pulmonary fibrosis
Pulmonary fibrosis, represented mainly by idiopathic pulmonary fibrosis (IPF), develops chronic and progressive changes in lung parenchyma with high mortality and limited therapeutic options. IPF as a representant of pulmonary fibrosis is a chronic pulmonary disease with a poor prognosis that can be often worse than many types of cancer. This disease occurs predominantly in adult individuals, to a greater extent in males, and is solely limited to lungs. IPF has been associated with the histopathological and/or radiological image of usual interstitial pneumonia (UIP) (1) . It is anticipated that the initial stages of the disease include in particular the chronic inflammation; therefore, corticosteroids and other drugs with anti-inflammatory and immunosuppressive effects are used at this stage of the disease. Lung tissue fibrosis occurs in the later stage of the disease where antifibrotic treatment (e.g. pirfenidone or nintedanib) is recommended, but these drugs only prevent the disease from deteriorating. Additional non-pharmacological approaches such as long-term oxygen therapy, pulmonary rehabilitation, or lung transplantation can be used (2) , as well.
Experimental models of pulmonary fibrosis
Animal models play an important role in the exploration of diseases because they allow understanding of the pathophysiological mechanisms of their formation in in vivo conditions. An ideal animal model should be the most imitating human illness, be highly reproducible and consistent, easy to execute, widely accessible, and not too expensive. The general benefits of animal models are related to the ability to reproduce complex genetic, biochemical, environmental, and phenotypic interactions. Creating animal models for chronic diseases is particularly challenging. Even more complicated is a situation with idiopathic pulmonary fibrosis (IPF) because the etiopathology is unclear and no trigger is known to induce all known IPF features on animals.
Over the years, however, various pre-clinical models of pulmonary fibrosis have been developed, which have been evoked using different animal species (mice, rats, dogs, guinea pigs, dogs, sheep). The most common are mice and rats due to the ease of handling, availability of reagents, and well-characterized immune systems (1, 3) . However, use of mice and rats is limited by the differences of their lungs to those of human, small size, as well as by their reduced sensitivity to cough (1, 3) . For instance, use of larger animals could enable to use a fibre-optic bronchoscope to deliver fibrogenic factor (e.g. bleomycin) topically to induce a more severe fibrosis in selected segments, which is more akin to pulmonary fibrosis in patients, while the whole-lung exposure to fibrogenic agent to smaller animals can be associated with more severe tissue damage and higher mortality of animals (3). In addition, use of larger animals enables to use additional investigational methods including high-resolution CT imaging or repetitive measurement of lung functions including gas exchange or to examine the histopathological changes and collagen content from the lung biopsies (3). Thereby, the progression of pulmonary fibrosis can be assessed more reliably on a smaller number of larger animals than on numerous small animals (3).
Pulmonary fibrosis can be caused by different fibrotic insults, routes of administration, and dosing regimes (single or repeated administration). Most of these models mimic some but never all of the characteristics of human IPF, especially the progressive and irreversible nature of this condition. Commonly used methods of induction of pulmonary fibrosis include lung damage by irradiation or instillation of bleomycin, fluorescein isothiocyanate (FITC), silicon dioxide (silica), or asbestos, with bleomycin being the most common inducer of experimental pulmonary fibrosis in animals (1, 3, 4) ( Table 1) .
Bleomycin model
Bleomycin model is the most frequently used model of pulmonary fibrosis; therefore, we decided to discuss this model in a more detailed manner. Bleomycin is a chemotherapeutic antibiotic with anticancer activity that was discovered by Umezawa in 1966. Its structure has been known since 1978 (5) and the total synthesis was performed in 1982 (6) . The use of bleomycin to induce pulmonary fibrosis in animal models is based on the fact that fibrosis is one of the major adverse effects of bleomycin in the treatment of human cancers. Bleomycin plays an important role in the treatment of lymphoma, squamous cell carcinomas, germ cell tumours, and malignant pleural effusion which it is injected intrapleurally. It is assumed that bleomycin causes breaks in one or both strands of DNA in the cancer cells, resulting in disruption of the cell cycle. This is probably due to chelation of metal ions and reaction of pseudo-enzyme with oxygen, resulting in the production of DNA-cleaving superoxides and hydroxide free radicals (7, 8) . Overproduction of reactive oxygen species can lead to an inflammatory response causing pulmonary toxicity, fibroblast activation, and subsequent fibrosis (9) . Bleomycin hydrolase, a bleomycin-inactivating enzyme, critically impacts the effects of this drug on various tissues. Lungs maintain low levels of this enzyme; therefore, they are susceptible to bleomycin-induced tissue damage (10) . Until now, mechanisms associated with the development of pulmonary fibrosis have not been fully known. Several studies have analysed various potential biological and molecular factors such as transforming growth factor beta-1 (TGF-1), tumour necrosis factor alpha (TNF-α), extracellular matrix components, chaperones, interleukins, and chemokines (6) . In addition, bleomycin may cause generalized endothelial damage and imbalance in the fibrinolytic system (11) .
Bleomycin has been shown to induce lung damage in various animal species -mice, hamsters, rats, rabbits, guinea pigs, dogs, and primates (12) (13) (14) . Although the effects of bleomycin have been investigated in many animal models, the results from these studies are highly inhomogeneous because bleomycin is administered in different doses and different routes. In intravenous delivery of bleomycin the initial lesions appear to the pulmonary endothelium and the epithelial damage including necrosis of type I cells, metaplasia of type II cells and deposition of collagen in the lungs occurs subsequently. However, fibrotic changes need 4-12 weeks to develop, while in some animals they can be absent (1) . Nowadays, bleomycin at a dose of 1.25 -4 U/kg is administered in general anaesthesia mainly via the intratracheal route -by direct transtracheal injection or by naso-or oro-tracheal instillation. Transtracheal injection requires a midline incision in the neck area which is sutured immediately after the injection of bleomycin. Transoral instillation is a nonsurgical alternative when bleomycin is given into the trachea via a transoral route during positioning of the animal on the angled surgery board (15, 16) . After bleomycin instillation the animals should be carefully monitored, with daily measurement of body weight and observation of their appearance, behaviour, and physiological measures. Of course, a special attendance should be paid to animals after surgical intervention. However, because the transoral method of delivery is less injurious for animals with lower mortality and post-delivery complications while having comparable distribution of bleomycin throughout the lungs, this delivery approach should be preferred not only for bleomycin model but also for other models where lung fibrosis is induced by intratracheal delivery of fibrogenic agent.
Bleomycin causes inflammatory and fibrotic reactions within a short time interval. In case of intratracheal administration, its action is even faster. The initial increase in proin - flammatory cytokines (interleukin (IL)-1, TNF-α, IL-6, interferon-γ) is followed by an increased expression of profibrotic markers (TGF-β1, fibronectin, procollagen-1) with a peak around 14 days after bleomycin administration. Inflammatory changes are gradually replaced by fibrotic changes around the 9th day after bleomycin administration (9) . In past the bleomycin model helped to clarify the role of cytokines, growth factors and signaling pathways that are likely to be involved in pulmonary fibrosis (17) . In addition, observations of changes in the bleomycin model helped to determine that TGF-β is one of the key factors in the development of pulmonary fibrosis. Subsequently, this model was used in the preclinical testing of nintedanib and pirfenidone (18) (19) (20) (21) and thereby contributed to their introducing in the clinical practice. However, the bleomycin model is essential for development and testing of variety of potentially beneficial treatments inhibiting TGF-β signalling (22) (23) (24) (25) , as well.
Advantages and disadvantages of the model: Bleomycin model is well-characterized, quite simple and rapid to develop, is reliable and reproducible, and, thus, it fulfills all the important criteria which are expected out of a good animal model. However, the development of fibrosis in mice is at least partially reversible beyond 28 days, irrespective of the type of intervention (26, 27) . The problem of spontaneous resolution could be theoretically solved by repetitive administration of lower bleomycin doses. However, longer persistence of fibrosis after this procedure was associated with significant increase in mortality of animals (28) . Since the bleomycin model lacks an aspect of the slow and irreversible development typical of IPF in patients (29) , this fact must be taken into account, e.g. in pre-clinical drug testing.
FITC model
Fluorescein isothiocyanate (FITC) is another substance used to evoke pulmonary fibrosis. When the FITC is administered directly into the airways, fluorescein acts as a hapten and attaches to other lung proteins and acts as a prolonged form. The fibrotic response to FITC develops over 2 to 4 weeks and can last up to 24 weeks (30) . The main advantage of FITC molecule is its fluorescence property that can identify the immunofluorescence areas of deposition and surrounding fibrosis in a given tissue. This model was described for the first time by Roberts et al. in 1995 (31) . Intratracheal administration of FITC to BALB/c mice caused a significant infiltration of mononuclear cells and neutrophils into the lung interstitium, primarily focused around respiratory bronchioles, and a generation of oedema and hyperplasia of alveolar epithelial cells. A significant increase in proteins concentration in the bronchoalveolar lavage fluid within the 1st week confirmed a generation of an acute lung injury (32) . FITC-induced model is dependent on Th2-lymfocytes producing profibrotic IL-13 in lungs.
Advantages and disadvantages of the model: FITC causes fibrotic changes in time relations similar to bleomycin and an additional advantage is its easy visualization by green fluorescence. However, there are several disadvantages: the solution of FITC must be prepared immediately before each administration, effectiveness of FITC can vary depending on the used batch and on the size of particles (30) , and the fibrotic response also highly varies with an absence of several histopathological features including fibro blast foci (33) .
Radiation-induced fibrosis model
Pulmonary fibrosis may be also induced by some non-chemical approaches in vivo, e.g. exposure to chest radiation. Radiation-induced fibrosis is dependent on the strain used in mice, with C57Bl/6 being the most sensitive (34) . It is a relatively slow procedure that leads to the formation of fibrosis within 24 weeks (35) . Irradiation causes a direct cell death of pneumocytes types I and II by DNA damage, followed by migration of macrophages into the damaged areas. Activated mononuclear cells then produce proinflammatory and profibro tic cytokines including TNF-α and TGF-β that are involved in the development of fibrosis. The rate of fibrosis is dependent on the dose of radiation, e.g. a dose of 10 to 20 Gy was used in mice (36) . Only one strong radiation effect is sufficient to induce the fibrotic process, but it may take up to 6 months for fibrosis to develop (35) .
Advantages and disadvantages of the model: This model is advantageous due to its ability to induce persistent fibrosis-like changes in lungs. However, the formation of fibrosis in this way takes a relatively long time and the costs of irradiation (including technical equipment for irradiation) can be high. This model also lacks some of the histopathological features observed in IPF patients such as complex fibroblast deposits (37) .
Silica model
Inhalation of silicate particles also leads to pulmonary fibrosis. The silica micro-or nanoparticles at a dose of 6-50 mg in 1 ml of saline per kg body weight can be experimentally administered via oropharyngeal, inhalation, or intratracheal aspiration (38) . In terms of silica sensitivity, the murine C3H/HeN and C57Bl/6 mice are the most suitable for this type of experiment. Silica induces development of fibrotic nodules that occur at the earliest 4 weeks after the administration. Although this model can be used to monitor fibrotic mediators, it does not uniquely replicate the nature of IPF. The extent of fibrosis is dependent on the kinetics of the supplied silica, which is highly heterogeneous, and also depends on the mode of administration, the dosage regimens, and the silica particle formulations. Creating intratracheal models is faster (fibrosis develops within 14-28 days) and cost-effective, while the aerosolized route of administration takes longer to produce fibrotic lesions (40 to 120 days) (39) . Interestingly, silica can induce a different fibrotic response in rats and mice. In rats the silica instillation caused chronic and progressive inflammation accompanied by overproduction of TNF-α, which was effectively blocked by anti-inflammatory therapy. In contrast, in mice the fibrotic response was associated with a limited and transient inflammation and overexpression of the anti-inflammatory cytokine IL-10 and anti-inflammatory therapy had no effect (40) .
Advantages and disadvantages of the model: The greatest advantage is the persistence of fibrotic lesions as a result of decreased clearance of the pulmonary silica particles (41) . However, this model requires a costly aerosol delivery device (if aerosolized) and a longer period for fibrosis development (4-16 weeks), while the reproducibility of this model is limited because of absence of several characteristic lesions of UIP and pulmonary conditions resembling more the lung silicosis than the lung fibrosis (1, 3) .
Asbestos model
Another model that recaptures the important form of human lung fibrosis is an exposure to asbestos (42) . Asbestos-induced pulmonary fibrosis models clearly differ from IPF by multiple histological findings. In some cases the UIP pattern may also be present (4). Following intratracheal administration of asbestos fibers, fibrosis is generated more centrally than subpleurally and changes in lungs are often unevenly distributed, while inhalation models form a pattern of damage to peripheral areas, as well. However, development of the disease may be prolonged, especially when chrysotile fibres are used (43) . The deposition of asbestos fibres triggers fibrotic changes by an increased apoptosis of alveolar epithelial cells and by overproduction of profibrotic cytokines by activated T-cells, all events leading to differentiation of myofibroblasts and production of extracellular matrix (44) .
Advantages and disadvantages of the model: The advantage is the persistence of fibrotic lesions. However, similarly to silica model, the reproducibility of this model is limited because of pulmonary conditions resembling more the lung asbestosis than the lung fibrosis.
A C T A M E D I C A M A R T I N I A N A 2 0 1 9 1 9 / 3 CONCLUSION Animal models of pulmonary fibrosis are an important tool for decrypting many aspects of pulmonary fibrosis pathogenesis. They represent irreplaceable preclinical models for hypothesis testing as well as for administration of potentially beneficial treatments. However, the diversity of individual experimental models of fibrosis requires that their advantages and limitations should be carefully considered before each experiment or project.
